View Older Stories View More Recent Stories

Feb 28, 2023 06:44PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 28, 2023 04:05PM Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments
Feb 28, 2023 09:00AM Sarepta Therapeutics Announces Call for Applications for the 6th Annual Route 79, The Duchenne Scholarship Program
Feb 21, 2023 08:30AM Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2022 Financial Results
Feb 17, 2023 08:31AM Sarepta Therapeutics (SRPT) Announces Initiation of VOYAGENE, a Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
Feb 17, 2023 08:30AM Sarepta Therapeutics Announces Initiation of VOYAGENE, a Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
Jan 31, 2023 06:20PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 9, 2023 01:29PM Sarepta Therapeutics (SRPT) Q4 net product revenues are expected to be approximately $235.5 million
Jan 9, 2023 01:28PM Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2022 Net Product Revenues
Jan 5, 2023 08:31AM Sarepta (SRPT) and Catalent (CTLT) Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate
Jan 5, 2023 08:30AM Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate
Jan 3, 2023 08:30AM Sarepta Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Dec 30, 2022 05:58PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 30, 2022 06:00PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 28, 2022 07:01AM Sarepta Therapeutics (SRPT) Announces That U.S. FDA has Accepted for Filing and Granted Priority Review for BLA for SRP-9001, Sarepta’s Gene Therapy for the Treatment of Ambulant Individuals with Du
Nov 28, 2022 07:00AM Sarepta Therapeutics Announces That U.S. FDA has Accepted for Filing and Granted Priority Review for the Biologics License Application for SRP-9001, Sarepta’s Gene Therapy for the Treatment of Ambul
Nov 23, 2022 08:30AM Sarepta Therapeutics to Present at the Evercore ISI HealthCONx Conference
Nov 2, 2022 04:05PM Sarepta Therapeutics Announces Third Quarter 2022 Financial Results and Recent Corporate Developments
Oct 31, 2022 06:00PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 26, 2022 08:30AM Sarepta Therapeutics to Announce Third Quarter 2022 Financial Results
Oct 7, 2022 08:31AM Sarepta Therapeutics (SRPT) Presents New Data from its Gene Therapy and RNA Platforms
Oct 7, 2022 08:30AM Sarepta Therapeutics Presents New Data from its Gene Therapy and RNA Platforms at World Muscle Society 2022
Sep 30, 2022 06:15PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 29, 2022 08:32AM Sarepta Therapeutics (SRPT) Submits BLA for SRP-9001 for the Treatment of Ambulant Patients with Duchenne Muscular Dystrophy
Sep 29, 2022 08:30AM Sarepta Therapeutics Submits Biologics License Application for SRP-9001 for the Treatment of Ambulant Patients with Duchenne Muscular Dystrophy
Sep 7, 2022 08:30AM Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2022-2023 Academic Year
Sep 6, 2022 08:45AM Sarepta Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
Sep 6, 2022 08:31AM Sarepta Therapeutics (SRPT) Announces That FDA has Lifted its Clinical Hold on SRP-5051 for the Treatment of Duchenne Muscular Dystrophy
Sep 6, 2022 08:30AM Sarepta Therapeutics Announces That FDA has Lifted its Clinical Hold on SRP-5051 for the Treatment of Duchenne Muscular Dystrophy
Aug 31, 2022 05:59PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 8, 2022 08:33AM Sarepta Therapeutics (SRPT) Announces Progress on the MyoAAV Program and Exclusive Licensing Agreement with The Broad Institute for MyoAAV Next-generation Capsids for Rare Genetic Diseases
Aug 8, 2022 08:30AM Sarepta Therapeutics Announces Progress on the MyoAAV Program and Exclusive Licensing Agreement with The Broad Institute for MyoAAV Next-generation Capsids for Rare Genetic Diseases
Aug 2, 2022 04:05PM Sarepta Therapeutics Announces Second Quarter 2022 Financial Results and Recent Corporate Developments
Jul 29, 2022 06:25PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jul 29, 2022 07:00AM Sarepta Therapeutics (SRPT) to Submit an Accelerated Approval BLA for its Gene Therapy SRP-9001 to Treat DMD
Jul 29, 2022 07:00AM Sarepta Therapeutics Announces Intent to Submit an Accelerated Approval Biologics License Application for its Gene Therapy SRP-9001 to Treat Duchenne Muscular Dystrophy
Jul 26, 2022 08:30AM Sarepta Therapeutics to Announce Second Quarter 2022 Financial Results and Recent Corporate Developments on August 2, 2022
Jul 6, 2022 08:15AM Sarepta Therapeutics' (SRPT) Investigational Gene Therapy SRP-9001 for DMD Demonstrates Significant Functional Improvements Across Multiple Studies
Jul 6, 2022 08:15AM Sarepta Therapeutics’ Investigational Gene Therapy SRP-9001 for Duchenne Muscular Dystrophy Demonstrates Significant Functional Improvements Across Multiple Studies
Jul 5, 2022 04:05PM Sarepta Therapeutics (SRPT) to Release New Data on SRP-9001 Tomorrow
Jul 5, 2022 04:01PM Sarepta Therapeutics to Share New Clinical Data and Integrated Analysis for SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy on July 6, 2022 at 8:30am ET
Jun 30, 2022 06:15PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 24, 2022 09:30AM Pre-Open Stock Movers 06/24: Zendesk Surges on Surprise Deal; LendingTree Falls on Lower Outlook (More...)
Jun 23, 2022 04:01PM Sarepta Therapeutics (SRPT) Reports Clinical Hold on SRP-5051 for the Treatment of Duchenne Muscular
Jun 23, 2022 04:01PM Sarepta Therapeutics Provides Update on SRP-5051 for the Treatment of Duchenne Muscular Dystrophy
Jun 2, 2022 04:08PM Sarepta Therapeutics (SRPT) Appoints Michael Chambers and Kathryn Boor to its Board
Jun 2, 2022 04:05PM Sarepta Therapeutics Appoints Michael Chambers and Kathryn Boor, Ph.D., to Its Board of Directors
Jun 2, 2022 08:30AM Sarepta Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
May 31, 2022 06:15PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 4, 2022 04:05PM Sarepta Therapeutics Announces First Quarter 2022 Financial Results and Recent Corporate Developments
View More Recent Stories View Older Stories